28.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$26.44
Aprire:
$28.095
Volume 24 ore:
1.34M
Relative Volume:
0.84
Capitalizzazione di mercato:
$2.65B
Reddito:
$522.75M
Utile/perdita netta:
$-558.99M
Rapporto P/E:
-4.3292
EPS:
-6.47
Flusso di cassa netto:
$-439.53M
1 W Prestazione:
+2.56%
1M Prestazione:
-23.95%
6M Prestazione:
-37.55%
1 anno Prestazione:
-38.00%
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Confronta RARE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RARE
Ultragenyx Pharmaceutical Inc
|
28.01 | 2.50B | 522.75M | -558.99M | -439.53M | -6.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-28 | Iniziato | William Blair | Outperform |
2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
2023-12-08 | Iniziato | Wells Fargo | Overweight |
2023-06-14 | Ripresa | Credit Suisse | Outperform |
2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
2023-01-18 | Ripresa | Canaccord Genuity | Buy |
2022-12-30 | Ripresa | H.C. Wainwright | Buy |
2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
2021-09-30 | Iniziato | H.C. Wainwright | Buy |
2021-08-19 | Iniziato | UBS | Sell |
2021-07-15 | Iniziato | Guggenheim | Neutral |
2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
2021-06-04 | Ripresa | Robert W. Baird | Neutral |
2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
2021-04-26 | Ripresa | Credit Suisse | Neutral |
2021-03-02 | Ripresa | Stifel | Buy |
2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
2020-11-24 | Ripresa | Evercore ISI | In-line |
2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
2019-08-02 | Ripresa | Wedbush | Outperform |
2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2019-02-22 | Ripresa | Raymond James | Outperform |
2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
2018-05-10 | Iniziato | Goldman | Neutral |
2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
2018-03-22 | Ripresa | Piper Jaffray | Overweight |
2018-02-21 | Reiterato | Stifel | Buy |
2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
2018-01-18 | Iniziato | Credit Suisse | Outperform |
2017-12-05 | Reiterato | Barclays | Equal Weight |
2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Ultragenyx Pharmaceutical Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
What drives Ultragenyx Pharmaceutical Inc. stock priceRapid portfolio appreciation - Autocar Professional
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
RARE ACTIVE INVESTIGATION: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
What analysts say about Ultragenyx Pharmaceutical Inc. stockUnmatched profit potential - jammulinksnews.com
Ultragenyx Pharmaceutical (RARE) Gets a Complete Response Letter for UX111 - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
Is Ultragenyx Pharmaceutical Inc. a good long term investmentConsistently high returns - jammulinksnews.com
Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
11 Best All-Time Low Stocks to Buy According to Analysts - Insider Monkey
William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) - MSN
Ultragenyx Grants Restricted Stock Units to New Employees, Expands Workforce and Focus on Rare Diseases. - AInvest
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation - ACCESS Newswire
Did You Suffer Losses in Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rare Disease Leader Ultragenyx Expands Team with 45,292 Stock Grants to New Hires - Stock Titan
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Investors to Reach Out - ACCESS Newswire
Ultragenyx stock hits 52-week low at $26.85 By Investing.com - Investing.com Canada
Published on: 2025-07-18 04:31:12 - Newser
Why Ultragenyx Pharmaceutical Inc. stock is on top investor watchlistsDouble Your Capital Alerts - Newser
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials By Investing.com - Investing.com South Africa
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials - Investing.com
Sarepta Therapeutics Announces Workforce Reductions as FDA Rejects Ultragenyx Rare Disease Drug Over Manufacturing Concerns - geneonline.com
Ongoing Securities Investigation into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) - Insider Monkey
Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Connect - ACCESS Newswire
Ultragenyx, Mereo in selloff after trial update on bone disorder therapy - MSN
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionMinimized Risk Trading Plan - Newser
US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder - MSN
Ultragenyx gets Complete Response Letter for Sanfilippo syndrome gene therapy - MSN
What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyFree Exclusive Access to Stock Gurus - Newser
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):